SCHEMBL5582233

SCHEMBL5582233

CNc1ncc2c(-c3cccc(Cl)c3)cc(C=O)c(OC)c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 5/20 0.40
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
CSNK2A1 P68400 1/20 0.38
SCN9A Q15858 5/20 0.38
MAP4K4 O95819 1/20 0.38
PDE4D Q08499 2/20 0.36
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
PDE5A O76074 1/20 0.35
CNR2 P34972 1/20 0.35
FLT1 P17948 1/20 0.35
FLT4 P35916 1/20 0.35
KDR P35968 1/20 0.35
STK4 Q13043 1/20 0.35
STK3 Q13188 1/20 0.35
SIK2 Q9H0K1 1/20 0.35
STK26 Q9P289 1/20 0.35
STK24 Q9Y6E0 1/20 0.35
CHEK1 O14757 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5582125 0.90 ADORA1 (0.38) ADORA1CSNK2A2CSNK2BCSNK2A1SCN9A
SCHEMBL5581783 0.87 ADORA1 (0.42) ADORA1CSNK2A2CSNK2BCSNK2A1SCN9A
SCHEMBL5581781 0.87 ADORA1 (0.42) ADORA1CSNK2A2CSNK2BCSNK2A1SCN9A
SCHEMBL5582181 0.86 ADORA1 (0.42) ADORA1CSNK2A2CSNK2BCSNK2A1SCN9A
SCHEMBL5582182 0.86 ADORA1 (0.42) ADORA1CSNK2A2CSNK2BCSNK2A1SCN9A
SCHEMBL5581799 0.84 FYN (0.41) ADORA1CSNK2A2CSNK2BCSNK2A1SCN9A
SCHEMBL5582085 0.84 CSNK2A2 (0.38) ADORA1CSNK2A2CSNK2BCSNK2A1SCN9A
SCHEMBL5581820 0.84 ADORA1 (0.43) ADORA1CSNK2A2CSNK2BCSNK2A1SCN9A
SCHEMBL5582080 0.84 CCNC (0.41) ADORA1CSNK2A2CSNK2BCSNK2A1JAK2
SCHEMBL5582074 0.84 CCNC (0.41) ADORA1CSNK2A2CSNK2BCSNK2A1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225308-A1 2-Amino Quinazoline Derivative KYOWA HAKKO KOGYO CO.,LTD. (JP) 2007-09-27 US disclosed
EP-1726584-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225308-A1 2-Amino Quinazoline Derivative AGTR2, ABL1, AGTR1 ADORA1 406/4885CSNK2A2 467/4885CSNK2B 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.